Unvaccinated Exposure
Without prior immunity, varicella-zoster spreads unchecked through the body.
- 250–500: Typical lesion count (unvaccinated child)
- 103–104°F: Peak fever (day 2–4)
- ~10 days: Illness duration (rash to full crusting)
- ~8 days: Contagious window (pre-rash through crusting)
A highly contagious airborne virus
Varicella-zoster spreads via respiratory droplets and direct contact.
One infected person can spread VZV to 90% of susceptible household contacts.
Rash progression
Papules become vesicles, then pustules, then crust over days.
Complication risk
Pneumonia, encephalitis, and skin infection can occur.
Vaccinated Exposure
Vaccination primes immune memory, but protection is not absolute.
- ~85%: 1-dose efficacy (against any varicella)
- ~98%: 2-dose efficacy (against any varicella)
- 5–15%: Breakthrough risk (per year, 1-dose regimen)
- ~95%: Severe disease cut (even if breakthrough occurs)
Live-attenuated vaccine
A weakened VZV strain trains antibodies and T-cells.
The Oka strain has been used safely worldwide since the 1970s.
Partial, not perfect, immunity
Antibody titers vary and can decline with time.
Two-dose schedule
A second dose substantially boosts durable protection.
Breakthrough Infection Occurs
Vaccinated individuals can still contract chickenpox from wild-type virus.
- ~1%/yr: 2-dose breakthrough rate (cumulative risk)
- <50: Typical lesion count (often fewer than 50)
- Atypical: Presentation (maculopapular, few vesicles)
- Rare / mild: Fever occurrence (below 38.9°C usually)
What "breakthrough" means
Infection occurring despite prior vaccination.
Breakthrough cases are still contagious, just less so.
Waning immunity
Antibody levels can fall gradually over years.
High viral load exposure
Intense household exposure can overwhelm defenses.
Attenuated Disease Course
Immune memory blunts the infection into a much lighter illness.
- 20–60: Lesion count (vs 250–500 unvaccinated)
- ~5 days: Illness duration (vs ~10 days unvaccinated)
- ~4 days: Contagious period (vs ~8 days unvaccinated)
- Much lower: Complication rate (fewer hospitalizations)
Fewer lesions
Immune memory limits how far the virus spreads.
Breakthrough rash is often mistaken for insect bites.
Milder fever
A blunted cytokine response keeps fever low.
Faster recovery
Memory T-cells speed up viral clearance.
Comparative Outcome
Vaccination does not always prevent infection — but it reshapes severity.
- ~85–90%: Lesion reduction (breakthrough vs wild-type)
- ~90%: Fever reduction (high fever rare in breakthrough)
- Lower: Transmission risk (shorter contagious period)
- Markedly milder: Overall severity (vaccine still highly protective)
Dense rash vs scattered spots
Density difference reflects viral containment.
Vaccinated breakthrough cases rarely need hospital care.
Public health impact
Vaccination sharply cuts severe varicella disease.
Herd protection
Shorter contagious windows slow community spread.